Your AI-Trained Oncology Knowledge Connection!

Advances in MRD Testing for Informed CRC Treatment : Episode 7

Opinion

Video

April 1, 2024

Evolution of MRD Testing in Colorectal Cancer

Author(s):

John L. Marshall, MD,Benjamin Weinberg, MD

The panel discusses how MRD testing has evolved as a clinical tool in colorectal cancer, highlighting the phase 2/3 COBRA study and its implications.

EP: 1.Treating Colorectal Cancer: Overview of MRD Testing and ctDNA

EP: 2.When is MRD Testing Performed in Colorectal Cancer Treatment?

EP: 3.MRD Testing Platforms in Colorectal Cancer

EP: 4.Testing for MRD in Colorectal Cancer

EP: 5.Colorectal Cancer: MRD Testing in the Community Setting

EP: 6.Practical Considerations in MRD Testing in CRC

Now Viewing

EP: 7.Evolution of MRD Testing in Colorectal Cancer

EP: 8.Patient Profile: A 52-Year-Old Woman With Colorectal Cancer

EP: 9.Colorectal Cancer: Updates from the GALAXY Arm in CIRCULATE-Japan

EP: 10.BESPOKE CRC: Study of ctDNA-Guided Therapy in Colorectal Cancer

EP: 11.Myths Surrounding Liquid Biopsy and ctDNA Testing for MRD

EP: 12.Patient Profile 2: A 35-Year-Old Man With Oligometastatic Colorectal Cancer

EP: 13.Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer

EP: 14.Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer: Part 2

EP: 15.CIRCULATE-NORTH AMERICA and Barriers to Enrollment

EP: 16.MRD Testing in CRC: Gaps in our Understanding and Potential Advancements

EP: 17.Trajectory of CRC Treatment Landscape

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 24th 2025 - Apr 25th 2026

online-activity

Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity

Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity

Latest Conference Coverage

Early ctDNA Clearance Is Associated With Response to Daraxonrasib in RAS-Mutant NSCLC

Dr Haldar on Outcomes for NeoAg-VAX With or Without Pembrolizumab in MSS mCRC

Retrospective Analysis Explores Cabozantinib/Nivolumab vs Lenvatinib/Pembrolizumab in Frontline Advanced RCC

Dr Tang on Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic ccRCC

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Evolution of MRD Testing in Colorectal Cancer

EP: 1.Treating Colorectal Cancer: Overview of MRD Testing and ctDNA

EP: 2.When is MRD Testing Performed in Colorectal Cancer Treatment?

EP: 3.MRD Testing Platforms in Colorectal Cancer

EP: 4.Testing for MRD in Colorectal Cancer

EP: 5.Colorectal Cancer: MRD Testing in the Community Setting

EP: 6.Practical Considerations in MRD Testing in CRC

EP: 7.Evolution of MRD Testing in Colorectal Cancer

EP: 8.Patient Profile: A 52-Year-Old Woman With Colorectal Cancer

EP: 9.Colorectal Cancer: Updates from the GALAXY Arm in CIRCULATE-Japan

EP: 10.BESPOKE CRC: Study of ctDNA-Guided Therapy in Colorectal Cancer

EP: 11.Myths Surrounding Liquid Biopsy and ctDNA Testing for MRD

EP: 12.Patient Profile 2: A 35-Year-Old Man With Oligometastatic Colorectal Cancer

EP: 13.Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer

EP: 14.Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer: Part 2

EP: 15.CIRCULATE-NORTH AMERICA and Barriers to Enrollment

EP: 16.MRD Testing in CRC: Gaps in our Understanding and Potential Advancements

EP: 17.Trajectory of CRC Treatment Landscape

Newsletter

Latest CME

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Addressing Unmet Needs in HER2+ Metastatic BTC

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Addressing Unmet Needs in HER2+ Metastatic BTC

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Latest Conference Coverage